Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc
Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!
£4.00
Continuing with the output of updated clinical guidelines from ENETS, this paper is unlike the others so far in 2022/23/24 where the guidelines were set against several clinical questons for particular scenarios (presumably common in the NET patient population). So far,the clinical guidelines have centred on Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) (Neuroendocrine Carcinoma (NEC) and Neuroendocrine Tumours (NET)).
The latest output comes in a different format than the GEP NEN output but is based on Lung NETs, i.e. well differeniated Lung NETs. I’m hoping it is a precurser to a set of updated Lung NEN guidelines. Although, as you will see there is no well differentiated grade 3 but a special category of well differentiated Lung NET with aggressive features. The Lung WHO 2021 classification of tumours (see Spotlight on Lung NENs) covered this special category (putting it into the large cell Lung NEC category as a placeholder). The same reference also failed to remove the ‘carcinoid‘ misnomer word, so my apologies for the use of this term in the attached reference link and in this post. However, still good to see output for Lung NETs. Worth pointing out that many Lung NEC are handled by Lung Multidiscplinary Teams (MDT), a slightly controversial point, particularly when the statistics for these Neuroendocrine Carcinomas (particulary small cell lung cancer (SCLC) are not inlcuded in overall NEN statistical data.
The format is based on a survey completed by thirty-four experts from 20 centres specialising in lung NET (I will in due course update my ‘Find a NET expert‘ section to incorporate this useful data).
Q1 and Q2 collected information about the medical specialist responding to the survey, who is the first point of contact for the patient, and the structure of the centre (type of structure, lung NET dedicated MDTB, number of lung NET dealing per year, and number of new lung NET dealing per year; details are shown in Table 1). |
Q3 and Q4 focused on the diagnostic investigations for specific clinical cases with potentially resectable disease (a peripheral or a centrally located lung NET lesion). |
Clinical case scenarios (Q5–11). |
Adjuvant treatment (Q12–15) |
Feasibility of conducting an adjuvant clinical trial (Q16–17) |
Follow-up protocols (Q18–20) |
Clinical cases (21, 22) |
Now read the reference material belowif you are interested in the output from this survey and the summarising information.
Click on the blue link below see read the discussion and the recommendations for each of those questions.
Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei, Justo P. Castano, Lynnette Fernandez-Cuesta, Christophe M. Deroose, Matthieu Foll, Clarisse Dromain, Nicholas Simon Reed, Martyn Caplin, Jaume Capdevila, Jenny Falkerby, Antongiulio Faggiano, Andrea Frilling, Enrique Grande, Rodney J. Hicks, Atsuko Kasajima, Beata Kos-Kudla, B. A. Krishna, Eric Lim, Anja Rinke, Simron Singh, Chrissie Thirlwell, Marco Volante, Thomas Walter
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Vitamin D deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) — but that does not automatically mean your deficiency is caused by
Words are very important to cancer patients, some people hang their hats on them and put their feet up, and some people google them until
Overview Many thanks for the support in January and February 2026. This is a double month newsletter due to my 27 day holiday! 2026 Blog
Vitamin B12 deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) – what that means is there is a chance your deficiency as
When I was a young lad, I didn’t seem to have a fear of heights, not that I got many chances to test it but
When I was diagnosed with metastatic Neuroendocrine Cancer in 2010, there’s a lot of milestones I doubted I would reach. One is today and I
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose
Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the
Subscribe to get the latest posts sent to your email.
